Khawla Abu Samra1,2, Merih Oray1,2,3, Nazanin Ebrahimiadib1,2, Stacey Lee1,2, Stephen Anesi1,2, C Stephen Foster1,2,4. 1. a Massachusetts Eye Research and Surgery Institution (MERSI) , Waltham , Massachusetts , USA. 2. b Ocular Immunology and Uveitis Foundation , Waltham , Massachusetts , USA. 3. c Istanbul University, Istanbul Faculty of Medicine , Department of Ophthalmology , Istanbul , Turkey. 4. d Harvard Medical School , Boston , Massachusetts , USA.
Abstract
PURPOSE: To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma. METHODS: Review of tertiary referral center records between 2005 and 2015. RESULTS: A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42%) and blurred vision (35%); 62% of patients had ocular and central nervous system involvement; 11% had systemic lymphoma; and 27% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77% of patients on initial biopsy, and in 100% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit. CONCLUSIONS: Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists.
PURPOSE: To describe clinical manifestations, diagnostic approaches, therapy, and outcomes of biopsy-proven intraocular lymphoma. METHODS: Review of tertiary referral center records between 2005 and 2015. RESULTS: A total of 51 eyes of 26 patients were included; mean age of onset was 60.42 years. Common ocular complaints included floaters (42%) and blurred vision (35%); 62% of patients had ocular and central nervous system involvement; 11% had systemic lymphoma; and 27% had only ocular involvement. Vitreous analysis was positive for malignant cells in 77% of patients on initial biopsy, and in 100% of patients on repeat biopsy. In total, 20/26 patients received systemic and topical treatment before IOL diagnosis was made; 25 patients received intravitreal methotrexate and/or rituximab; one patient received intracameral rituximab. All patients achieved remission by their final visit. CONCLUSIONS:Intraocular lymphoma often masquerades as intraocular inflammation, resulting in delayed or misdiagnosis with subsequent inappropriate management. Optimal therapy is a challenge for oncologists and ophthalmologists.
Authors: Muhammad Hassan; Muhammad Sohail Halim; Rubbia Afridi; Nam V Nguyen; Quan Dong Nguyen; Yasir J Sepah Journal: Int J Retina Vitreous Date: 2021-11-24
Authors: Josephus L M van Rooij; Klaudia A Tokarska; Ninette H Ten Dam-van Loon; Peter H Wessels; Tatjana Seute; Monique C Minnema; Tom J Snijders Journal: Cancers (Basel) Date: 2022-06-16 Impact factor: 6.575